Wire · opportunities
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
The FDA approved Lyrfigtu (lirafugratinib) for second-line treatment of cholangiocarcinoma with FGFR2 fusion or rearrangement, demonstrating significant efficacy and a manageable safety profile. Elevar Therapeutics will make Lyrfigtu available in the U.S. by Q4 2026.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 22 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
Oncology founders focused on targeted therapies now face a higher bar as FDA prioritises precision inhibitors with clearer mechanisms. You can pivot towards FGFR2-focused drugs or partner to access refractory cholangiocarcinoma patients seeking better second-line options.
◆ Coverage
3 sources · first reported 22 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics